Buy Lomustine (Gleostine) online
Price: 1,500 UAH
Known as original brand(s)
Gleostine
Buy Lomustine (Gleostine) online with delivery. Browse medicines that contain Lomustine, compare doses and prices.
Lomustine (CCNU) is a synthetic bifunctional alkylating antineoplastic agent belonging to the nitrosourea class, originally marketed under the brand name Ceenu. It is widely used in neuro-oncology and hematology for the treatment of primary and metastatic brain tumors, lymphomas, and selected solid malignancies.
The mechanism of action of lomustine relies on its high lipid solubility, allowing it to rapidly cross the blood-brain barrier (BBB). Inside cells, lomustine decomposes to generate active alkylating and carbamoylating intermediates that cross-link DNA and RNA strands, inhibit key enzymatic pathways, and disrupt cancer cell replication.
Clinical administration of lomustine is particularly valuable in managing central nervous system malignancies (glioblastoma, astrocytoma) where water-soluble chemotherapeutic agents fail to penetrate effectively.
Indications
Lomustine is indicated in clinical oncology for the following conditions:
- Brain Tumors: Treatment of primary central nervous system tumors (glioblastoma, anaplastic astrocytoma, medulloblastoma) as primary therapy or upon relapse.
- Hodgkin's Lymphoma: Combination chemotherapy in patients with relapsed or refractory Hodgkin's disease.
- Non-Hodgkin's Lymphomas: Management of progressive non-Hodgkin's lymphomas.
- Other Solid Tumors (Off-label): Malignant melanoma and lung cancer in specialized protocols.
Dosage and administration
Lomustine is administered exclusively via the oral route:
- Recommended Dosage (Adults & Pediatrics): As a single agent, the standard dose is 100 to 130 mg/m² of body surface area administered as a single oral dose every 6 weeks.
- Retreatment Criteria: Subsequent courses should not be administered until bone marrow recovery has occurred (platelets above 100,000/mcL, leukocytes above 4,000/mcL).
- Reduced Dosing: Patients with compromised bone marrow function should have their starting dose reduced to 100 mg/m² every 6 weeks.
- Administration Technique: Capsules should be taken on an empty stomach (1 to 2 hours before or after meals) with water to minimize nausea. Administered as a single dose per cycle.
- Monitoring: Complete blood counts with platelet differentials must be monitored weekly for at least 6 weeks following administration due to delayed myelosuppression.